This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

–News Direct–

By Johnny Rice, Benzinga

Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), were recently guests on Benzinga’s All Access.

Cingulate is a biotechnology company developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer.

Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/this-biotech-just-cleared-a-big-fda-hurdle-in-its-quest-to-improve-adhd-treatment-341277340